We’re proud to highlight that Tyrolpath, the largest private pathology lab in western Austria, is the first lab in Austria to adopt MSK-IMPACT®-Flex powered with SOPHiA DDM™, marking a major milestone for precision oncology in the country.

With approximately 45,000 new cancer diagnoses reported each year, there is a strong need for comprehensive genomic profiling (CGP) to identify actionable mutations, especially as precision oncology becomes more central in clinical practice.

“I have met with the experts at Memorial Sloan Kettering Cancer Center before, and having the opportunity to utilize their assays in my own lab thanks to SOPHiA GENETICS is going to be a transformative step for cancer testing in Austria. Leveraging the power of the SOPHiA DDM™ Platform will help us advance precision oncology for our Austrian patients.” Said Peter Obrist, CEO, Tyrolpath.

Built on the proven backbone of MSK-IMPACT® combined with the cloud-based SOPHiA DDM™ Platform, MSK-IMPACT® Flex empowers laboratories to achieve flexible, cost-efficient insights into key solid tumor biomarkers based on individual patient cases.

🧬 At SOPHiA GENETICS, we believe in empowering labs to accelerate innovation. With this collaboration, we’re taking another step forward in bringing cutting-edge CGP testing to Austria.

Learn more about our comprehensive genomic profiling applications: https://www.sophiagenetics.com/sophia-ddm-for-genomics/solid-tumors/cgp/